Hepatitis C Virus Envelope Glycoprotein E2 Glycans Modulate Entry, CD81 Binding, and Neutralization

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Virology

• Publication date

  2007-05-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.00459-07PMID 17507469PMCID PMC1951298
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Flaviviridae :T he Viruses and Their Replication

  2007cited by this paper
• Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry

  2007cited by this paper
• Cyanovirin-N Inhibits Hepatitis C Virus Entry by Binding to Envelope Protein Glycans*

  2006cited by this paper
• A Conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr Motif in Hepatitis C Virus Glycoprotein E2 Is a Determinant of CD81 Binding and Viral Entry

  2006cited by this paper
• Different Domains of CD81 Mediate Distinct Stages of Hepatitis C Virus Pseudoparticle Entry

  2006cited by this paper
• Characterization of host‐range and cell entry properties of the major genotypes and subtypes of hepatitis C virus

  2005cited by this paper
• Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Glycoproteins

  2005influential reference
• L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus.

  2004cited by this paper
• HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing.

  2004cited by this paper
• Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection.

  2004cited by this paper
• Neutralizing antibody response during acute and chronic hepatitis C virus infection.

  2004cited by this paper
• CD81 is an entry coreceptor for hepatitis C virus.

  2004cited by this paper
• Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin.

  2004cited by this paper
• Hepatitis C Virus Glycoprotein E2 Contains a Membrane-proximal Heptad Repeat Sequence That Is Essential for E1E2 Glycoprotein Heterodimerization and Viral Entry*

  2004cited by this paper
• CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection

  2004cited by this paper
• Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection.

  2004cited by this paper
• Viral hepatitis B.

  2003cited by this paper
• Establishment of B-Cell Lymphoma Cell Lines Persistently Infected with Hepatitis C Virus In Vivo and In Vitro: the Apoptotic Effects of Virus Infection

  2003cited by this paper
• L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus

  2003cited by this paper
• Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes

  2003cited by this paper
• DC-SIGN and L-SIGN Are High Affinity Binding Receptors for Hepatitis C Virus Glycoprotein E2*

  2003cited by this paper
• Cell Entry of Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin and the SR-B1 Scavenger Receptor*

  2003cited by this paper
• Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR

  2003cited by this paper
• Humoral immune response against hepatitis C virus.

  2003cited by this paper
• Binding of the Hepatitis C Virus E2 Glycoprotein to CD81 Is Strain Specific and Is Modulated by a Complex Interplay between Hypervariable Regions 1 and 2

  2003cited by this paper
• In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes

  2003cited by this paper
• Antibody neutralization and escape by HIV-1

  2003cited by this paper
• Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins.

  2003cited by this paper
• Inaugural Article: Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease

  2002cited by this paper
• Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.

  2002cited by this paper
• Placement of the Structural Proteins in Sindbis Virus

  2002cited by this paper
• Quantitative Expression and Virus Transmission Analysis of DC-SIGN on Monocyte-Derived Dendritic Cells

  2002cited by this paper
• Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding.

  2002cited by this paper
• The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

  2002cited by this paper
• Protection against persistence of hepatitis C.

  2002cited by this paper
• Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus.

  2001cited by this paper
• Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2.

  2001cited by this paper
• In search of hepatitis C virus receptor(s).

  2001cited by this paper
• Locations of carbohydrate sites on alphavirus glycoproteins show that E1 forms an icosahedral scaffold.

  2001cited by this paper
• The Fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH.

  2001cited by this paper
• Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication detected only in liver.

  2001cited by this paper
• Conservation of the Conformation and Positive Charges of Hepatitis C Virus E2 Envelope Glycoprotein Hypervariable Region 1 Points to a Role in Cell Attachment

  2001cited by this paper
• DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans

  2001cited by this paper
• Hepatitis C virus infection.

  2001cited by this paper
• A model for the hepatitis C virus envelope glycoprotein E2

  2000cited by this paper
• Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits

  2000cited by this paper
• Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding.

  2000cited by this paper
• Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus

  2000cited by this paper
• Characterization of Hepatitis C Virus E2 Glycoprotein Interaction with a Putative Cellular Receptor, CD81

  1999cited by this paper
• Perspectives for a vaccine against hepatitis C virus.

  1999cited by this paper
• Analysis of a successful immune response against hepatitis C virus.

  1999cited by this paper
• Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees

  1999cited by this paper
• Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex.

  1999cited by this paper
• Hepatitis C virus infection: virus/host interactions

  1998cited by this paper
• Binding of hepatitis C virus to CD81.

  1998cited by this paper
• Hepatitis: an overview of important issues.

  1997cited by this paper
• A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.

  1996cited by this paper
• Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment.

  1995cited by this paper
• Low pH induces swiveling of the glycoprotein heterodimers in the Semliki Forest virus spike complex.

  1995cited by this paper
• The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution

  1995cited by this paper
• Susceptibility of human T-lymphotropic virus type I infected cell line MT-2 to hepatitis C virus infection.

  1995cited by this paper
• Transfusion-associated hepatitis

  1985cited by this paper
• Viral hepatitis.

  1970cited by this paper

• Targeted Removal of HCV E2 N2 N-Glycan Is Associated with Improved Immune Responses in Mice.

  2026cites this paper
• Glycoengineering of the hepatitis C virus E2 glycoprotein improves biochemical properties and enhances immunogenicity

  2025cites this paper
• Glycoengineering of the hepatitis C virus E2 glycoprotein leads to improved biochemical properties and enhanced immunogenicity

  2025cites this paper
• Update on Hepatitis C Vaccine: Results and Challenges

  2024cites this paper
• Lectibodies as antivirals.

  2024cites this paper
• Neutralizing antibodies to block viral entry and for identification of entry inhibitors.

  2024cites this paper
• Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies.

  2023cites this paper
• Structure and Role of O-Linked Glycans in Viral Envelope Proteins.

  2023cites this paper
• HCV E1 influences the fitness landscape of E2 and may enhance escape from E2-specific antibodies

  2023cites this paper
• Repurposing of drug molecules from FDA database against Hepatitis C virus E2 protein using ensemble docking approach

  2023cites this paper
• Site specific N- and O-glycosylation mapping of the spike proteins of SARS-CoV-2 variants of concern

  2023cites this paper
• Glikozylacja białek w infekcjach bakteryjnych i wirusowych

  2023cites this paper
• Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens.

  2023cites this paper
• Dissecting the Heterogeneous Glycan Profiles of Recombinant Coronavirus Spike Proteins with Individual Ion Mass Spectrometry.

  2023cites this paper
• Innate and Adaptive Immunopathogeneses in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma

  2022cites this paper
• Site Specific N- and O-glycosylation mapping of the Spike Proteins of SARS-CoV-2 Variants of Concern

  2022cites this paper
• Glycosylation of viral proteins: Implication in virus–host interaction and virulence

  2022cites this paper
• Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence

  2022cites this paper
• Mechanisms of HCV resistance to broadly neutralizing antibodies.

  2021cites this paper
• Carbohydrates-based diagnosis, prophylaxis and treatment of infectious diseases: Special emphasis on COVID-19

  2021cites this paper
• Structural O-Glycoform Heterogeneity of the SARS-CoV-2 Spike Protein Receptor-Binding Domain Revealed by Native Top-Down Mass Spectrometry

  2021cites this paper
• Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production

  2021cites this paper
• Hepatitis C virus E2 envelope glycoprotein produced in Nicotiana benthamiana triggers humoral response with virus‐neutralizing activity in vaccinated mice

  2021cites this paper
• Altered N-/O-Glycosylation Sites On The Receptor-Binding Domain (RBD) in COVID-19 Are Related To Coronavirus Infection And Pathogenesis.

  2021cites this paper
• Structural and Biophysical Characterization of the HCV E1E2 Heterodimer for Vaccine Development

  2021cites this paper
• Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies

  2021influential citation
• Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial

  2021cites this paper
• In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus

  2021cites this paper
• Structural O-Glycoform Heterogeneity of the SARS-CoV-2 Spike Protein Receptor-Binding Domain Revealed by Top-Down Mass Spectrometry

  2021cites this paper
• Glycosylation in viral hepatitis.

  2021cites this paper
• Coronaviruses' sugar shields as vaccine candidates.

  2020cites this paper
• Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine

  2020cites this paper
• Hepatitis C virus vaccine design: focus on the humoral immune response

  2020cites this paper
• The Impacts of Antivirals on the Coronavirus Genome Structure and Subsequent Pathogenicity, Virus Fitness and Antiviral Design

  2020cites this paper
• Flexibility and intrinsic disorder are conserved features of hepatitis C virus E2 glycoprotein

  2020cites this paper
• Impact of Protein Glycosylation on the Design of Viral Vaccines.

  2020cites this paper
• Multiscale simulations examining glycan shield effects on drug binding to influenza neuraminidase

  2020cites this paper
• Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans

  2019cites this paper
• Identifying immunologically-vulnerable regions of the HCV E2 glycoprotein and broadly neutralizing antibodies that target them

  2019cites this paper
• Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations

  2019cites this paper
• Current Progress and Challenges in the Development of a Hepatitis C Virus Vaccine

  2019cites this paper
• Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells

  2019cites this paper
• Antigenicity and Immunogenicity of Differentially Glycosylated HCV E2 Envelope Proteins Expressed in Mammalian and Insect Cells

  2019cites this paper
• Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes

  2018cites this paper
• Role of Macrophage Subsets in CD8+ T Cell Dysfunction in Chronic HCV Infection

  2018cites this paper
• Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies

  2018cites this paper
• Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?

  2018cites this paper
• Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus

  2018cites this paper
• Lectins as Promising Therapeutics for the Prevention and Treatment of HIV and Other Potential Coinfections

  2018cites this paper
• Predicting the Effectiveness of Hepatitis C Virus Neutralizing Antibodies by Bioinformatic Analysis of Conserved Epitope Residues Using Public Sequence Data

  2018cites this paper
• Viral glycoproteomes: technologies for characterization and outlook for vaccine design

  2018cites this paper
• Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry

  2018cites this paper
• Motif-Aware PRALINE: Improving the alignment of motif regions

  2018cites this paper
• Global aspects of viral glycosylation

  2018influential citation
• An update on mechanism of entry of white spot syndrome virus into shrimps

  2017cites this paper
• Innate and Adaptive Immune Responses in Chronic HCV Infection.

  2017cites this paper
• Comparative Proteomics Reveals Important Viral-Host Interactions in HCV-Infected Human Liver Cells

  2016cites this paper
• B Cell Responses and Control of HCV Infection

  2016cites this paper
• Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy

  2016cites this paper
• Evolution of the Humoral Response during HCV Infection: Theories on the Origin of Broadly Neutralizing Antibodies and Implications for Vaccine Design.

  2016cites this paper
• Viral evasion and challenges of hepatitis C virus vaccine development.

  2016cites this paper
• Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

  2016cites this paper
• DETERMINANTS OF NEUTRALIZATION IN ENVELOPE PROTEINS OF HEPATITIS C VIRUS

  2016cites this paper
• N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.

  2016cites this paper
• The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.

  2016cites this paper
• Hepatitis C Virus Resistance to Carbohydrate-Binding Agents

  2016cites this paper
• Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies

  2016cites this paper
• Extrémités 3’ de l’ARN du Virus de l’Hépatite C : structures et Rôles dans la réplication du génome

  2016cites this paper
• The dynamic properties of the Hepatitis C Virus E2 envelope protein unraveled by molecular dynamics

  2016cites this paper
• Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant

  2015cites this paper
• Current and future prophylactic vaccines for hepatitis C virus

  2015cites this paper
• Étude de la résistance du virus de l'hépatite C à des molécules ciblant les N-glycanes

  2015influential citation
• Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, Challenge

  2015cites this paper
• Roles of Lipoproteins and Apolipoproteins in Particle Formation of Hepatitis C Virus.

  2015cites this paper
• Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus.

  2015cites this paper
• Roles of lipoprotein and apolipoprotein in HCV infection.

  2015cites this paper
• Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection

  2015cites this paper
• Structural Basis for Penetration of the Glycan Shield of Hepatitis C Virus E2 Glycoprotein by a Broadly Neutralizing Human Antibody*

  2015cites this paper
• Structural characterization of viral envelope glycoproteins

  2014cites this paper
• Global fold and backbone dynamics of the hepatitis C virus E2 glycoprotein transmembrane domain determined by NMR.

  2014cites this paper
• Generation of infectious HCV pseudo typed particles and its utilization for studying the role of CD81 & SRBI receptors in HCV infection

  2014cites this paper
• The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development

  2014cites this paper
• Non-random Escape Pathways from a Broadly Neutralizing Human Monoclonal Antibody Map to a Highly Conserved Region on the Hepatitis C Virus E2 Glycoprotein Encompassing Amino Acids 412–423

  2014cites this paper
• The past, present and future of neutralizing antibodies for hepatitis C virus

  2014cites this paper
• THE INTERNATIONAL ARABIC JOURNAL OF ANTIMICROBIAL AGENTS

  2014cites this paper
• Immunologic, metabolic and genetic factors in hepatitis C virus infection.

  2014cites this paper
• Immune control and failure in HCV infection—tipping the balance

  2014cites this paper
• Architecture of the hepatitis C virus E1 glycoprotein transmembrane domain studied by NMR.

  2014cites this paper
• Recent advances in HCV entry

  2014cites this paper
• Ficolin-2 Inhibits Hepatitis C Virus Infection, whereas Apolipoprotein E3 Mediates Viral Immune Escape

  2014cites this paper
• Innate and adaptive immune responses in HCV infections.

  2014cites this paper
• Influence of the hepatitis C genotype on the antiviral immune response

  2014cites this paper
• Immune Escape whereas Apolipoprotein E3 Mediates Viral Ficolin-2 Inhibits Hepatitis C Virus Infection,

  2014cites this paper
• CD81 and Hepatitis C Virus (HCV) Infection

  2014cites this paper
• Collaboration between a Soluble C-Type Lectin and Calreticulin Facilitates White Spot Syndrome Virus Infection in Shrimp

  2014cites this paper
• Spot Syndrome Virus Infection in Shrimp Lectin and Calreticulin Facilitates White Collaboration between a Soluble C-Type

  2014cites this paper
• Role of N-linked glycans in the interactions of recombinant HCV envelope glycoproteins with cellular receptors.

  2014cites this paper
• Tetraspanins

  2013cites this paper
• The Role of CD81 in HCV and Plasmodium Infection

  2013cites this paper
• Post-translational modifications of hepatitis C viral proteins and their biological significance.

  2013cites this paper